ABCSG 56 / SASCIA Overview
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
| Study Start: | AT: FPI 09/2022 Global: FPI 12/2020 (GER) |
| Coordinating Investigator: | AT: Balic, Marija |
| Sample Size: | AT: 50 Global: 1332 |
| Study Design: (Click to enlarge) |
 |
Share on